Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe

Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe

Granted European Patent Covering 2'-Methyl-2'-Fluoro Nucleosides for Treating Hepatitis C Virus

CAMBRIDGE, Mass., March 14, 2014 (GLOBE NEWSWIRE) -- Idenix
Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment of
human viral diseases, today announced that it has filed patent
infringement lawsuits against Gilead Sciences, Inc. (Nasdaq:GILD)
and/or certain of its subsidiaries in each of three countries - France,
Germany and the United Kingdom.
The lawsuits allege that Gilead infringes Idenix's recently-granted,
co-owned European patent EP 1 523 489 that covers 2'-methyl-2'-fluoro
nucleosides for treating the hepatitis C virus. In these lawsuits,
Idenix is seeking remedies with respect to Gilead's marketing and sales
of drugs containing sofosbuvir, which Idenix believes infringes its
European patent.
"We are pleased to have been granted this European patent, and today's
filings further confirm Idenix's conviction in the strength of our
intellectual property portfolio and the resolve we have to protect it,"
said Maria Stahl, senior vice president and general counsel at Idenix.
"Idenix has invested significant resources in nucleoside drug discovery
and in building a valuable intellectual property portfolio -- and we
will continue to vigorously defend it. These proceedings, along with
the U.S. infringement actions we filed in December, are part of a
concerted effort to safeguard these technologies."
Other Ongoing Patent Disputes
Idenix has several ongoing litigation and administrative matters
involving Gilead Sciences, Inc., and/or certain of its subsidiaries. In
December 2013, Idenix announced it filed two lawsuits against Gilead: a
patent infringement lawsuit in the United States District Court in
Boston, Massachusetts (Idenix U.S. Patents 6,914,054 and 7,608,597) and
a separate patent infringement and interference lawsuit in the United
States District Court in Wilmington, Delaware (Idenix U.S. Patent
7,608,600 and Gilead U.S. Patent 8,415,322).
In February 2012, the U.S. Patent and Trademark Office, or USPTO,
initiated a patent interference between one of Idenix's co-owned patent
applications and a patent owned by Gilead. In January 2014, the USPTO
determined that Idenix is not entitled to priority of invention and
judgment was entered in favor of Gilead. Idenix challenged this
decision in the U.S. District Court for the District of Delaware.
In December 2013, the USPTO declared a second patent interference
between Idenix's U.S. Patent 7,608,600 and Gilead's U.S. Patent
Application 11/854,218, both related to the use of certain
2'-methyl-2'-fluoro nucleoside compounds to treat HCV infections.
In August 2013, Idenix filed a request with the Chinese Patent Office's
Patent Re-examination Board, or the PRB, to invalidate Gilead's Chinese
Patent No. ZL.200480019148.4.
Gilead Sciences has also filed suit against Idenix in various
jurisdictions outside the United States (Canada, Norway and Australia)
to invalidate granted Idenix patents covering certain
2'-methyl-2'-fluoro nucleoside compounds and their use in treating HCV
or other Flaviviridae viruses.
Idenix Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is a biopharmaceutical Company engaged in the discovery
and development of drugs for the treatment of human viral diseases.
Idenix's current focus is on the treatment of patients with hepatitis C
infection. For further information about Idenix, please refer to
This press release contains "forward-looking statements" for purposes
of the safe harbor provisions of The Private Securities Litigation
Reform Act of 1995, including but not limited to the statements
regarding the Company's future business and financial performance. For
this purpose, any statements contained herein that are not statements
of historical fact may be deemed forward-looking statements. Without
limiting the foregoing, the words "expect," "plans," "will," and
similar expressions are also intended to identify forward-looking
statements, as are expressed or implied statements with respect to the
Company's litigation strategy. Actual results may differ materially
from those indicated by such forward-looking statements as a result of
risks and uncertainties, including but not limited to the following:
the Company's ability to maintain and enforce patent and other
intellectual property protection for its product candidates and its
discoveries. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause actual results to
be materially different from any future results, performance or
achievements expressed or implied by such statements. These and other
risks which may impact management's expectations are described in
greater detail under the heading "Risk Factors" in the Company's annual
report on Form 10-K for the year ended December 31, 2013 as filed with
the Securities and Exchange Commission (SEC) and in any subsequent
periodic or current report that the Company files with the SEC.
All forward-looking statements reflect the Company's estimates only as
of the date of this release (unless another date is indicated) and
should not be relied upon as reflecting the Company's views,
expectations or beliefs at any date subsequent to the date of this
release. While Idenix may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so, even if the Company's estimates change.
CONTACT: Idenix Pharmaceuticals Contact:
        Teri Dahlman (617) 995-9807

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

A U.S. appeals court called Maryland's groundbreaking price-hike law unconstitutional, sending legislators back to the drawing board.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.